On the stock market since 1983, it operates in the world of health and science. It has 16,700 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
An average decline of 7% a year over the last 4 years — the most striking risk in this picture.
The gap is $2.4B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 43% below its peak. The market has trimmed its expectations for the company.
The average analyst price target is $167 — 45% above today’s price.
It pays out $0.28 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 17% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 60 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, PKI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PKI is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.